FDA staff cuts impacting crucial international drug factory inspections, potentially jeopardizing the safety of medications used by millions. ProPublica reveals safety concerns and staff depletion.
ProPublica reveals FDA's loophole allowing over 150 drugs from banned factories with mold/filth to enter the US, raising safety concerns and potential patient harm.
A bipartisan bill aims to penalize US medicine firms charging higher prices than other rich nations. Revlimid's price disparity highlights the issue. The debate involves research costs and government intervention.
